Results 161 to 170 of about 11,063,016 (345)

Associations of the fat-free mass index and the fat mass index with the risk of developing diabetes and prediabetes in US adults: a nationally representative cross-sectional study

Lipids in Health and Disease
Background Obesity and overweight, as determined by the body mass index (BMI), are harmful to metabolic health. However, the BMI can not reflect body composition or fat distribution. The fat-free mass index (FFMI) and the fat mass index (FMI) can provide
Da Liu, You-Lan Lei, Li Zhang, Wenyao Wang, Chunli Shao, Qing Zhou, Haiping Liu, Jun Wen, Jingjia Wang, Chen Li, Yiming Luo, Jingxin Rao, Yukun Shi, Gang Liu, Jie Yang, Mingqi Zheng, Yi-Da Tang   +16 more
doaj   +1 more source

The Role of Objectively Measured, Altered Physical Activity Patterns for Body Mass Index Change during Inpatient Treatment in Female Patients with Anorexia Nervosa [PDF]

, 2018
Celine Lehmann, Tobias Hofmann, Ulf Elbelt, Matthias Rose, Christoph U. Correll, Andreas Stengel, Verena Haas   +6 more
openalex   +1 more source

Methylation scores for smoking, alcohol consumption, and body mass index and risk of seven types of cancer [PDF]

, 2021
Pierre‐Antoine Dugué, Chenglong Yu, Allison Hodge, Ee Ming Wong, Jihoon E. Joo, Chol‐Hee Jung, Daniel F. Schmidt, Enes Makalic, Daniel D. Buchanan, Gianluca Severi, Dallas R. English, John L. Hopper, Roger L. Milne, Graham G. Giles, Melissa C. Southey   +14 more
openalex   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Muscle mass versus body mass index as predictor of adverse outcome

Journal of Cachexia, Sarcopenia and Muscle, 2021
Dion Groothof, Adrian Post, Harmke A. Polinder‐Bos, Bouke P.C. Hazenberg, Reinold O.B. Gans, Stephan J.L. Bakker   +5 more
doaj   +1 more source

Diagnosis and body mass index effects on hippocampal volumes and neurochemistry in bipolar disorder [PDF]

, 2017
David J. Bond, Leonardo Evangelista da Silveira, Erin L. MacMillan, Ivan J. Torres, Donna J. Lang, Wayne Su, William G. Honer, Raymond W. Lam, Lakshmi N. Yatham   +8 more
openalex   +1 more source

Uniform multifractal structure of stable trees

, 2015
In this work, we investigate the spectrum of singularities of random stable trees with parameter $\gamma\in(1,2)$. We consider for that purpose the scaling exponents derived from two natural measures on stable trees: the local time $\ell^a$ and the mass ...
Balança, Paul
core  

Infrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma

Molecular Oncology, EarlyView.
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff, Manuela Moritz, Dennis Eggert, Anna Worthmann, Joerg Heeren, Henrike Zech, Till S. Clauditz, Waldemar Wilczak, Hartmut Schlüter, Christian S. Betz, Arne Böttcher, Jan Hahn   +11 more
wiley   +1 more source

Relationship Between Plantar Pressure, Body Mass Index and Balance in Children: A Cross-Sectional Study [PDF]

Mostafa S. Ali, Sobhy M. Aly, Mahmoud Usama   +2 more
openalex   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source